Recent News

• 08.13.2025 - LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.13.2025 - LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 05.14.2025 - LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
• 05.14.2025 - LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
• 04.16.2025 - LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
• 04.16.2025 - LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
• 03.28.2025 - LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Recent Filings

• 08.04.2025 - 8-K Current report
• 08.04.2025 - SC TO-C Written communication relating to an issuer or third party
• 08.04.2025 - EX-99.1 EX-99.1
• 08.04.2025 - SC14D9C Written communication relating to third party tender offer
• 08.04.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.13.2025 - 8-K Current report
• 05.27.2025 - DEFR14A Revised definitive proxy soliciting materials
• 05.23.2025 - 8-K Current report
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.28.2025 - ARS Annual Report to Security Holders